| Income statement (USD) | FY 2025 ended Jun 30, 2025 | FY 2024 ended Jun 30, 2024 | FY 2023 ended Jun 30, 2023 | FY 2022 ended Jun 30, 2022 | FY 2021 ended Jun 30, 2021 | FY 2020 ended Jun 30, 2020 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | |||
| Research and development | 5.55M | 5.44M | 6.39M | 5.78M | 6.11M | 4.70M |
| Operating expenses | 9.59M | 8.52M | 8.94M | 8.11M | 8.74M | 8.00M |
| Operating income | -9.59M | -8.52M | -8.94M | -8.11M | -8.74M | -8.00M |
| EBITDA | -8.86M | -7.77M | -8.20M | -7.40M | -8.05M | -7.31M |
| Interest expense | 149 | 49.8K | 938 | 5.1K | 85.4K | 93.7K |
| Income before tax | -8.11M | -8.82M | -13.45M | |||
| Income tax | 0 | |||||
| Net income | -9.47M | -8.29M | -8.59M | -8.11M | -8.82M | -13.45M |
| EPS | -0.63 | -0.70 | -0.74 | -0.70 | -0.81 | |
| EPS (diluted) | -0.63 | -0.70 | -0.74 | -0.70 | -0.81 | -2.39 |
| Diluted shares | 15.12M | 11.87M | 11.63M | 11.53M | 10.90M |
From Nanoviricides, Inc.'s 10-K and 10-Q filings with the SEC. Fiscal years are the company's own, so they may not match the calendar. A blank cell means the company did not report that line. New to this? Read income statement or reading a 10-K.
Revenue, earnings, margins and balance sheet trends drawn by TradingView from its own data, so figures can differ slightly from the SEC table above.